A Study for Patients with Eczema (Atopic Dermatitis) who Find Topical Treatments Fail to Control or Cause an Allergic Reaction

Aim

A new therapy is needed to help treat patients whose Atopic Eczema is poorly controlled by commonly prescribed treatments applied to the skin. This Phase 2 clinical study is investigating the effectiveness of a new subcutaneous drug for the treatment of Atopic Eczema.

Eligibility

Patients must

  • Male and female
  • 18-65 years old
  • Diagnosed with moderate to severe eczema
  • Currently or a history of topical treatment use with inadequate results or an intolerance to

 

 Patients must not:

  • Suffer from any skin condition other than Atopic Eczema, which is treated differently
  • Have a history of drug or alcohol abuse
  • Suffer from sever heart disease, HIV or Hep B/Hep C

 

Locations

15 sites across the US

Open

  • Medical Research South, Charleston, South Carolina
  • Dawes Fretzin Clinical Research Group, Indianapolis, Indiana 
  • Pinnacle Research Group, Anniston, Alabama 
  • Altman Dermatology, Arlington Heights, Illinois 
  • PMG Research of Charlotte, Charlotte, North Carolina

 

Opening March/April

  • Oregon Health & Science University, Portland, Oregon
  • New York University Medical Center PRIME, Lake Success, New York 
  • MUSC, Charleston, North Carolina 
  • University of Texas Health Science Center at Houston, Houston, Texas 
  • University of Michigan, Ann Arbor, Michigan 
  • Northwestern University Feinberg School of Medicine, Chicago, Illinois 
  • University Hospitals Case Medical Center, Cleveland, Ohio 
  • Wake Forest University, Winston-Salem, North Carolina 
  • Rush Center for Clinical Studies – RRI, Chicago, Illinois 
  • UCSD Dermatology Clinical Trials Unit, San Diego, California

 

Sponsor & Collaborators

Chugai & TrialReach

Click here to see if you are eligible